China Cord Blood (NYSE: CO) reported earnings on Feb. 26. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended Dec. 31 (Q3), China Cord Blood met expectations on revenues and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue expanded significantly. GAAP earnings per share dropped.

Gross margins grew, operating margins expanded, net margins contracted.

Revenue details
 China Cord Blood booked revenue of $19.4 million. The one analyst polled by S&P Capital IQ predicted revenue of $19.5 million on the same basis. GAAP reported sales were 59% higher than the prior-year quarter's $15.0 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 EPS came in at $0.07. The one earnings estimate compiled by S&P Capital IQ forecast $0.05 per share. GAAP EPS of $0.07 for Q3 were 22% lower than the prior-year quarter's $0.09 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
 For the quarter, gross margin was 81.1%, 400 basis points better than the prior-year quarter. Operating margin was 45.0%, much better than the prior-year quarter. Net margin was 22.5%, much worse than the prior-year quarter.

Looking ahead
 Next quarter's average estimate for revenue is $18.8 million. On the bottom line, the average EPS estimate is $0.04.

Next year's average estimate for revenue is $77.1 million. The average EPS estimate is $0.21.

Investor sentiment
 The stock has a one-star rating (out of five) at Motley Fool CAPS, with 29 members out of 48 rating the stock outperform, and 19 members rating it underperform. Among 15 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), five give China Cord Blood a green thumbs-up, and 10 give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on China Cord Blood is buy, with an average price target of $5.50.

Is China Cord Blood the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.